A Phase I/II Study of Ganetespib in Combination With Doxorubicin in Solid Tumors (Phase I) and Refractory Small Cell Lung Cancer (Safety Dose Expansion, Phase II)
Phase of Trial: Phase I/II
Latest Information Update: 27 Apr 2018
Price : $35 *
At a glance
- Drugs Ganetespib (Primary) ; Doxorubicin
- Indications Small cell lung cancer; Solid tumours
- Focus Adverse reactions
- 12 Oct 2016 Status changed from recruiting to discontinued.
- 09 Sep 2015 Interim results (n=6) presented at the 16th World Conference on Lung Cancer.
- 14 Oct 2014 New trial record